Leukemia Clinical Trials

Showing 1481-1500 of 10,987 trials

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NCT04686682

This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study. These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.

NSCLCSCLCCRPC+5 more

Jacobio Pharmaceuticals Co., Ltd.152 participantsStarted May 2021

Tianjin, Tianjin Municipality, China

Enrolling By InvitationNA

Comparison Interventions on Kinetic and Kinematic Parameters

NCT07326475

Currently, it is difficult to find studies in the literature comparing proprioception exercises with the effect of manual therapy on improving balance, and in the long run it may translate into improved activity, functionality and injury prevention in athletes, when planning training or therapy, e.g. in patients after ankle sprains.

Young Football PlayersAnkle Sprain Prevention

Medical University of Gdansk45 participantsStarted Nov 2025

Gdansk, Poland

RECRUITINGPhase 1

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

NCT04872478

This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia

Meryx, Inc.50 participantsStarted Apr 2022

Atlanta, Georgia, United States • Atlanta, Georgia, United States • New York, New York, United States

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Comparison Interventions on Kinetic and Kinematic Parameters

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Related Searches

Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

A Prospective Randomized Controlled Trial of Dual-Mobility Components in Primary THA

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The Optimal Measurement Time for the New Gallbladder Function Assessment Method

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer

The Geriatric Emergency Department Pharmacologic Harm Prevention Project

Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia

Evaluation of the Anterior Tibialis Tendon Using Elastography in Patients With Hallux Valgus

Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors

Problem-Solving Therapy for Cancer Caregivers in Outpatient Palliative Care

An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis